Issue link: http://osercommunicationsgroup.uberflip.com/i/709455
C h a i n D r u g s t o r e D a i l y M o n d a y, A u g u s t 8 , 2 0 1 6 6 6 ALENDRONATE SODIUM ORAL SOLUTION FROM TAGI PHARMA In 2013, TAGI Pharma, Inc., announced the launch of its Alendronate Sodium Oral Solution, 70mg/75mL, once weekly, bone resorption suppression agent in the United States and its territories, posses- sions and protectorates. This FDA- approved oral solution is the sole source generic alternative to Merck & Co., Inc.'s FOSAMAX ® (alendronate sodium) Oral Solution and is indicated for the treat- ment of osteoporosis in postmenopausal women. In postmenopausal women, alen- dronate increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral com- pression fractures), and as treatment to increase bone mass in men with osteo- porosis. Alendronate Sodium Oral Solution (NDC#51224-301-10) is the only Alendronate Oral Solution on the market, the only generic Alendronate that's not a tablet, covered by Medicaid and most Medicare, has increased insurance cover- age, and is stocked and available at your preferred wholesaler. Contraindications are: abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia; inability to stand or sit upright for at least 30 minutes; do not administer alen- dronate sodium oral solution to patients at increased risk of aspiration; hypocal- cemia; hypersensitivity to any compo- nent of this product; hypersensitivity reactions including urticaria and angioedema have been reported. Visit www.tagipharma.com to view Alendronate Sodium Oral Solution full prescribing information which includes indications for use and additional impor- tant safety information. Thomas Anderson, Executive President, said, "Alendronate Oral Solution represents a key step forward in the implementation of TAGI Pharma's business plan to bring differentiated products to the marketplace." Kenny Harrington, Vice President of Sales and Marketing of TAGI Pharma, said, "Alendronate Sodium Oral Solution a d d r e s s e s unmet needs in the mar- ket for a liq- u i d Alendronate product, and compliments the TAGI strategy to pro- vide unique products to underserved cus- tomers." "TAGI Pharma, Inc. was established to target the generic retail market," said Thomas Anderson, "and our product selection for TAGI Pharma is focused on higher barriers to entry and limited com- petition, where there are market expan- sion opportunities in the retail market, as well as the non-retail sector currently being serviced by Precision Dose, our Parent Company. Keys to our success have been a thorough understanding of the markets we compete in and identifi- cation of profitable product opportunities that provide a value-add to our cus- tomers, with a foundation always grounded in product quality and high service level performance." Visit TAGI Pharma at booth #2322. For more information, go to www.tagi pharma.com or call 855.225.8244. EXECUTING SUCCESSFUL FORMULARY WIN/PULL THROUGH PROGRAMS WITH PDQ PDQ Communications has a proven track record in providing the most innovative formulary announcements in direct mail and email within the pharmaceutical industry. One of the biggest challenges that pharmaceutical companies encounter is timely com- munications. PDQ will strategize your program to ensure your national for- mulary or state specific win is seen by your target audience expeditiously, attaining the leverage needed with an important win. The company's top-notch sales and production teams will provide insight into the most cutting edge programs available. Whether it is its clear envelope designed to showcase your flashcard, or an envelope with variable teaser copy to highlight each plan approval, its formula- ry mailings get your message noticed. Complement your formulary announce- ment with an email program to further accelerate and reinforce your message, while broadening your reach with a mul- tichannel campaign. PDQ's formulary email campaigns are tailored to the appropriate healthcare professional with a special emphasis on the particular plan approval. Add an echo email (a repeat of the initial email with openers suppressed) at half the cost and boost your open rate. Whatever your managed care needs may be, its highly-experienced account managers will provide valuable, innova- tive, timely and cost-effective ideas to get your message delivered. Let PDQ Communications be your partner for all of your non-personal healthcare promotional needs. PDQ is there when you need them and there in a flash. Visit PDQ Communications at booth #2157. VITAMINS, NUTRITIONAL SUPPLEMENTS FROM SIRIO Sirio Nutrition is a global manufacturer and product developer of vitamins and nutritional supplements. Sirio provides a range of oral dosage products that include softgels, gummy, two-piece capsules, tablets, powders and oral liq- uids. Sirio Nutrition gummies make nutrition taste great! Sirio's gummies are gelatin or pectin based, offering consumers a tastier, more pleasant way to ingest vitamins and supplements. With a robust R&D team, Sirio can adjust the sugar content to meet the needs of different market groups. Based upon the sugar content, Sirio has classified its gummies as sugar-free, low sugar and sugar. Sirio gummy types can be coated with oil or sugar, resulting in different taste and appear- ance. When it comes to gummy flavors, Sirio R&D has the capability to custom formulate with natural or artificial fla- vors. This all depends on customer needs. Gummy shapes and sizes play a role in making nutrition fun, especially with children. Sirio has extensive capa- bilities to manufacture just about any shape you can think of. From a bear figure, dinosaur, orange slice and smil- ing face, Sirio has you covered. Sirio's comprehensive product portfolio encompasses these product categories: immunity and antioxidant, circulatory and heart health, cognitive and memo- ry, eye health, digestive health, sports nutrition, weight management, sleep, bone, prenatal health and throat cool- ing. Sirio packaging capabilities pro- vide options to package your product in China or the United States. Capabilities include clear plastic bot- tles, dis- play box, plastic bot- tle with mini bag or sachets. It can also ship bulk product and let the customer handle the packaging. Current production capacity continues to meet market demand, and with the projected growth of the gummy cate- gory, Sirio has invested by breaking ground on a new manufacturing plant that will start operation in 2018, dou- bling current gummy production capacity. Product innovation is one of the building blocks to Sirio's success. Sirio plans to innovate the gummy business by offering product types such as center filled, swirl colors and multi colors. It is also investigating different gelling agents. Visit Sirio at booth #1461. For more information, go to www.siriopharm.com or call 336.624.8426